Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.
about
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsA large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathwayEpigenetic modulators as therapeutic targets in prostate cancerExperimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.Epigenomics and ovarian carcinoma.Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression.The epigenome as a potential mediator of cancer and disease prevention in prenatal development.Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor - belinostat - in glioblastoma cell lines: a preliminary report.Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancerSynergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.Manipulating the epigenome for the treatment of urological malignancies.Epigenetics of neurological cancers.Finding the place of histone deacetylase inhibitors in prostate cancer therapy.Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors.A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101).A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin.Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors
P2860
Q21198868-0B8CF6BC-E673-4D22-8403-2820E1E681BBQ21562478-50FA3C7B-AE56-4B5B-A567-211BE2AE4499Q28071912-EAF38D86-5EE6-4069-9767-8190E16871EAQ34297701-EA383B68-137E-4840-813F-45EF5B2387F1Q34645445-0A102FD4-C874-4CBB-A086-4C583E9C46ACQ35636575-07C8D55A-37B0-4377-8D4B-2CBA57B03924Q35686880-ED1CAC0D-8A20-4065-BB20-C4670849023AQ35857477-71D5217E-D974-4146-980F-E7D85D5B86DBQ36990438-F3CC1ABA-FD92-48A9-9639-A27625160B9FQ37222794-E4EDA9BA-F0EF-4389-937C-AFDD8533B527Q37274993-43F83B11-CD1E-4F3B-ACF9-42681EB8181BQ37400663-C760C6C8-7E25-4C1B-BDD6-F354D6A99420Q37524412-526B9488-2860-42B3-81CD-129733821C96Q37650610-E480B3A3-FA2A-4E71-900A-1039091E92CBQ37960198-05DFC72C-089C-45EF-AD23-DB526CB660CBQ38335697-AB1D5EE6-8EAE-4DF3-8D97-43080DC58D59Q38840647-226A91FC-5FC7-47D7-BC3D-704A80BDDA26Q39051716-25782E3B-494D-4317-8C19-12BF2A567337Q39287526-35E3CD4C-75B8-4258-857A-F54768B3FAA3Q39503952-5186DA03-3E44-444B-89F5-18CAD42ABAF8Q39847974-36FF689E-DF37-4A0B-A4FE-710139BB9011Q47637390-5A77AD85-4FA7-4036-B99D-F5EF02EF2F5AQ58698929-FE1CF591-3B57-4A41-8C57-CE96FB27CF75
P2860
Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Activity of the histone deacet ...... cal models of prostate cancer.
@en
type
label
Activity of the histone deacet ...... cal models of prostate cancer.
@en
prefLabel
Activity of the histone deacet ...... cal models of prostate cancer.
@en
P2093
P2860
P356
P1476
Activity of the histone deacet ...... cal models of prostate cancer.
@en
P2093
Evan Mills
Gulshan Ara
Henri S Lichenstein
Michael Jeffers
William J LaRochelle
Xiaozhong Qian
P2860
P304
P356
10.1002/IJC.23243
P577
2008-03-01T00:00:00Z